Alterity Therapeutics Limited [NASDAQ: ATHE] surged by $0.19 during the normal trading session on Wednesday and reaching a high of $1.52 during the day while it closed the day at $1.44. The company report on April 21, 2021 that ATH434 protects brain cells and improves motor function in Parkinsonian disorder.
Oral presentation at the American Academy of Neurology.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) virtual annual meeting.
Alterity Therapeutics Limited stock has also gained 9.09% of its value over the past 7 days. However, ATHE stock has declined by -16.28% in the 3 months of the year. Over the past six months meanwhile, it has lost -27.27% and gained 7.46% year-on date.
The market cap for ATHE stock reached $57.93 million, with 22.06 million shares outstanding and 15.43 million shares in the current float. Compared to the average trading volume of 647.17K shares, ATHE reached a trading volume of 77054568 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Alterity Therapeutics Limited [ATHE]:
The Average True Range (ATR) for Alterity Therapeutics Limited is set at 0.10, with the Price to Sales ratio for ATHE stock in the period of the last 12 months amounting to 2057.73. The Price to Book ratio for the last quarter was 1.19.
ATHE stock trade performance evaluation
Alterity Therapeutics Limited [ATHE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.09. With this latest performance, ATHE shares dropped by -11.11% in over the last four-week period, additionally sinking by -27.27% over the last 6 months – not to mention a rise of 125.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATHE stock in for the last two-week period is set at 51.23, with the RSI for the last a single of trading hit 57.77, and the three-weeks RSI is set at 48.63 for Alterity Therapeutics Limited [ATHE]. The present Moving Average for the last 50 days of trading for this stock 1.5874, while it was recorded at 1.3040 for the last single week of trading, and 1.7384 for the last 200 days.
Alterity Therapeutics Limited [ATHE]: An insightful look at the core fundamentals
Return on Total Capital for ATHE is now -116.98, given the latest momentum, and Return on Invested Capital for the company is -113.53. Return on Equity for this stock declined to -113.53, with Return on Assets sitting at -90.26. When it comes to the capital structure of this company, Alterity Therapeutics Limited [ATHE] has a Total Debt to Total Equity ratio set at 0.47. Additionally, ATHE Total Debt to Total Capital is recorded at 0.47, with Total Debt to Total Assets ending up at 0.34. Long-Term Debt to Equity for the company is recorded at 0.01, with the Long-Term Debt to Total Capital now at 0.01.
Reflecting on the efficiency of the workforce at the company, Alterity Therapeutics Limited [ATHE] managed to generate an average of -$1,121,400 per employee.Alterity Therapeutics Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.30 and a Current Ratio set at 12.30.
Alterity Therapeutics Limited [ATHE]: Insider Ownership positions
There are presently around $1 million, or 3.70% of ATHE stock, in the hands of institutional investors. The top three institutional holders of ATHE stocks are: MORGAN STANLEY with ownership of 582,097, which is approximately 30.521% of the company’s market cap and around 18.70% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 321,500 shares of the stock with an approximate value of $0.4 million in ATHE stocks shares; and SABBY MANAGEMENT, LLC, currently with $0.23 million in ATHE stock with ownership of nearly New of the company’s market capitalization.
Positions in Alterity Therapeutics Limited stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 5 institutional holders increased their position in Alterity Therapeutics Limited [NASDAQ:ATHE] by around 483,058 shares. Additionally, 0 investors decreased positions by around 0 shares, while 4 investors held positions by with 623,694 shares. The mentioned changes placed institutional holdings at 1,106,752 shares, according to the latest SEC report filing. ATHE stock had 1 new institutional investments in for a total of 185,843 shares, while 0 institutional investors sold positions of 0 shares during the same period.